By Hendra Lukman 
Every moment, the bone marrow diligently generates millions of fresh blood and immune cells. This ceaseless renewal, a marvel of biological engineering, hinges on a precisely orchestrated balance. This intricate ecosystem relies on hematopoietic stem cells (HSCs), the progenitors of all blood cell types, supported by a network of stromal cells and a symphony of immune signals. However, as individuals age or face chronic inflammatory conditions, this delicate equilibrium can falter, paving the way for potentially serious blood disorders. A groundbreaking international study, detailed in a recent publication, illuminates how subtle yet profound changes within the bone marrow’s supportive microenvironment can precede and fuel the development of conditions like clonal hematopoiesis of indeterminate potential (CHIP) and myelodysplastic syndromes (MDS), ultimately increasing the risk of aggressive blood cancers.
The Silent Erosion of Bone Marrow Health
The bone marrow microenvironment, often referred to as the bone marrow niche, is far more than just a passive scaffold for blood cell production. It is a dynamic and interactive milieu where stromal cells, immune cells, and blood stem cells constantly communicate. This communication is critical for maintaining the normal self-renewal and differentiation of HSCs. However, this finely tuned relationship becomes increasingly vulnerable with age. The cumulative effects of aging, persistent low-grade inflammation (often termed "inflammaging"), or even the accumulation of minor genetic errors within stem cells, known as somatic mutations, can disrupt this crucial intercellular dialogue.
When communication breaks down, normal stem-cell renewal can be compromised. Simultaneously, HSCs that acquire specific mutations can gain a competitive advantage, expanding their numbers and dominating the stem cell pool without being effectively regulated. This phenomenon gives rise to CHIP, a condition that has become increasingly recognized in recent years. CHIP is characterized by the presence of these expanded, mutated HSC clones but typically without any overt symptoms in affected individuals. Despite its asymptomatic nature, CHIP is a significant risk factor. Studies indicate that individuals with CHIP face a tenfold increased risk of developing hematological malignancies, such as leukemia, and a doubled likelihood of experiencing cardiovascular disease and premature death.
A related, yet distinct, disorder is myelodysplastic syndrome (MDS). MDS also involves the expansion of clonal HSCs, but in this condition, the primary issue is the inefficient production of mature blood cells. This leads to a gradual decline in bone marrow function, resulting in cytopenias – deficiencies in one or more types of blood cells. MDS affects a notable percentage of older adults, with incidence rates reaching up to 20 in every 100,000 adults over 70. A significant concern with MDS is its potential to progress. Approximately 30% of MDS cases will inevitably advance to acute myeloid leukemia (AML), an aggressive and often rapidly fatal form of blood cancer.
Until now, the precise contribution of the bone marrow microenvironment to the initiation and progression of these disorders has remained a significant enigma, largely obscuring potential therapeutic avenues.
Mapping the Hidden Cellular Remodeling
To unravel the complex interplay between cellular changes and disease development, an international research consortium, co-led by Dr. Judith Zaugg from the European Molecular Biology Laboratory (EMBL) and the University of Basel, and Dr. Borhane Guezguez from the University Medical Center Mainz (UMC Mainz), embarked on an ambitious project. Their work, drawing upon samples from the established BoHemE cohort study in collaboration with Professor Uwe Platzbecker at the National Center for Tumor Diseases (NCT) Dresden, aimed to create a comprehensive molecular and spatial map of the human bone marrow microenvironment.
The researchers employed a suite of cutting-edge technologies to achieve unprecedented detail. Single-cell RNA sequencing allowed them to analyze the gene expression profiles of individual cells, revealing their types and functional states. Biopsy imaging provided crucial spatial context, showing where different cell populations reside within the bone marrow tissue. Proteomics offered insights into the protein landscape, detailing the molecular machinery at play. Furthermore, co-culture models enabled them to study cellular interactions in a controlled laboratory setting.
The analysis encompassed bone marrow samples from healthy donors, including those who were identified as having CHIP but were otherwise asymptomatic, and from patients diagnosed with MDS. The results of this extensive investigation unveiled a surprising and critical cellular shift that begins long before any clinical signs of disease manifest. The research team identified a gradual replacement of the resident mesenchymal stromal cells (MSCs) – the cells that normally provide essential support and cues for HSC function – by a distinct population of inflammatory stromal cells.
"I was surprised to observe such pronounced remodeling of the bone marrow microenvironment already in individuals with CHIP, although the underlying cause-and-effect relationships remain unclear," stated Dr. Zaugg, a co-senior author of the study, EMBL Group Leader, and Professor at Basel University. This observation underscores that the changes within the bone marrow niche are not merely a consequence of overt disease but can be an early, initiating factor.
The Pro-Inflammatory Cascade
These newly identified inflammatory MSCs (iMSCs) exhibit a distinct functional profile compared to their healthy counterparts. Instead of supporting normal stem cell activity, iMSCs produce significant quantities of interferon-induced cytokines and chemokines. These signaling molecules act as potent attractants and activators for specific immune cells, notably interferon-responsive T cells. Once activated, these T cells, in turn, amplify the inflammatory response, creating a self-perpetuating cycle. This creates a "feed-forward loop" that sustains chronic inflammation within the bone marrow. Such persistent inflammation is detrimental; it disrupts the delicate processes of normal blood formation and can also contribute to detrimental vascular changes within the marrow itself, further compromising its function.
Unraveling the Drivers of Inflammation
A key question for the researchers was whether the mutated hematopoietic cells themselves were directly triggering this inflammatory cascade in MDS. To investigate this, they employed a sophisticated computational method called SpliceUp, developed by co-lead author and EMBL alumnus Maksim Kholmatov in collaboration with colleagues from the Karolinska Institute. SpliceUp is designed to identify mutated cells within single-cell datasets by detecting aberrant RNA-splicing patterns, a hallmark of genetic alterations. This allowed the team to effectively separate mutated from non-mutated cells.
Remarkably, their analysis revealed that in MDS, the mutated hematopoietic stem cells did not appear to be the primary instigators of the inflammatory response observed in the microenvironment. Instead, the study suggests that the inflammatory network within the bone marrow niche becomes dominant, gradually displacing the normal regenerative structures.
"Another striking observation was that MDS stem cells couldn’t trigger stromal cells to produce CXCL12, an important signal that triggers blood cells to settle in the bone marrow. This failure may help explain why the bone marrow stops working properly," commented Dr. Karin Prummel, a co-lead author and EMBL postdoc. CXCL12 plays a vital role in anchoring hematopoietic stem and progenitor cells within their niche, ensuring their proper location and function. Its absence or reduced production by stromal cells could lead to stem cells migrating away from their supportive environment, contributing to bone marrow dysfunction.
Echoing this sentiment, Maksim Kholmatov, also a co-lead author and EMBL alumnus, stated, "It was quite surprising to see the lack of a direct inflammatory effect that we could attribute to the mutant cells. However, when viewed in the context of changes in the T cell and stromal compartments, it underlines the importance of the bone marrow microenvironment in shaping disease progression." This highlights a paradigm shift: the focus of disease development might not solely reside within the mutated cells but within the supportive environment that harbors them.
Inflammation: An Early Architect of Blood Disease
The collective findings of this research strongly indicate that chronic inflammation plays a pivotal and early role in the pathogenesis of blood disorders originating from the bone marrow. Crucially, this study elevates the bone marrow microenvironment, or niche, from a passive bystander to a central therapeutic target. By shifting the therapeutic focus from solely targeting mutated stem cells to addressing the entire ecosystem that supports them, this research opens up new and promising avenues for early intervention and prevention strategies.
The implications for clinical practice are significant. For older adults who are identified as having CHIP, even in the absence of symptoms, interventions aimed at mitigating inflammation could be beneficial. This might include the use of anti-inflammatory drugs or therapies specifically designed to modulate interferon signaling pathways. Such treatments could potentially help preserve normal bone marrow function and slow or even prevent the progression of CHIP to more aggressive conditions like MDS or AML.
Furthermore, the research suggests that combining targeted therapies that act on the mutated cells with treatments that modulate the bone marrow microenvironment could be a powerful strategy to halt or reverse disease progression. The identification of specific molecular signatures of iMSCs and interferon-responsive T cells also presents an opportunity to develop early diagnostic biomarkers. These biomarkers could help identify individuals at elevated risk, allowing for proactive monitoring and intervention.
"Our findings reveal that the bone marrow microenvironment actively shapes the earliest stages of malignant evolution," emphasized Dr. Guezguez, Principal Investigator in the Department of Hematology at UMC Mainz and co-senior author. "As advances in molecular profiling allow us to detect pre-leukemic states years before clinical onset, understanding how stromal and immune cells interact provides a foundation for preventive therapies that intercept disease progression before leukemia develops." This forward-looking perspective highlights the potential for truly preventative medicine in the realm of blood cancers.
Inflammaging and the Broader Health Horizon
The impact of these findings extends beyond the immediate concern of blood disorders. The study provides valuable insights into the broader phenomenon of "inflammaging" – the low-level, chronic, and systemic inflammation that is increasingly recognized as a significant contributor to a wide range of age-related diseases. These include not only cancers but also cardiovascular disease, metabolic disorders, and neurodegenerative conditions.
The bone marrow, once viewed primarily as a site for blood cell manufacturing, is now understood to be both a victim of and a contributor to systemic inflammatory aging. By elucidating the intricate interactions between immune cells and stromal cells that drive these inflammatory changes within the bone marrow, this research offers a compelling model. This model can be applied to investigate similar inflammatory remodeling processes in other myeloid malignancies and even in advanced stages of leukemia.
Dr. Zaugg cautioned that while the current findings are based on cross-sectional data, studying these processes over time is crucial. "It will be crucial to study these processes over time; our current findings are based on cross-sectional data," she stated. "This has important implications for therapies that replace malignant cells but leave the bone marrow niche intact, such as blood stem cell transplantation. We are now investigating to what extent the niche retains a ‘memory’ of disease, which could shape how it responds to new, healthy stem cells." This raises important questions about the long-term efficacy of treatments like stem cell transplantation if the underlying inflammatory microenvironment is not addressed. The concept of niche "memory" suggests that even after the introduction of healthy stem cells, the pre-conditioned inflammatory niche might still exert a negative influence.
The research published by Dr. Zaugg and Dr. Guezguez’s teams is complemented by a parallel study examining the MDS bone marrow microenvironment, also published in Nature Communications. This complementary work, led by Dr. Marc Raaijmakers from the Erasmus MC Cancer Institute in Rotterdam, collectively offers a more comprehensive and integrated view of inflammatory remodeling that occurs during the nascent stages of bone marrow disease. Together, these studies represent a significant leap forward in understanding the complex biological underpinnings of age-related blood disorders and their connection to systemic inflammation.
The collaborative effort involved researchers from numerous esteemed institutions, including UMC Mainz, University of Basel, University Hospital Dresden, Karolinska Institute Sweden, The Jackson Laboratory USA, Sorbonne University France, and various partner institutions of the German Cancer Consortium (DKTK), such as the German Cancer Research Center (DKFZ) and NCT Dresden. The significant undertaking was made possible through substantial funding from programs like the DKTK-CHOICE programme, an ERC grant (EpiNicheAML) awarded to Judith Zaugg, the Marie Skłodowska-Curie Actions (MSCA)-funded ITN ENHPATHY, EMBO, the Swiss National Foundation, and the José Carreras Leukemia Foundation. This multi-institutional and well-funded collaboration underscores the global importance and complexity of the research.
